Danaher Co. (NYSE:DHR) Shares Sold by Citizens Business Bank

Citizens Business Bank lessened its position in shares of Danaher Co. (NYSE:DHR) by 3.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,619 shares of the conglomerate’s stock after selling 472 shares during the quarter. Citizens Business Bank’s holdings in Danaher were worth $2,919,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of DHR. Wellington Management Group LLP increased its holdings in Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares during the period. Allen Investment Management LLC increased its stake in shares of Danaher by 1,440.7% in the third quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after acquiring an additional 1,028,976 shares during the period. J.P. Morgan Private Wealth Advisors LLC purchased a new position in shares of Danaher during the third quarter worth $178,850,000. Alecta Tjanstepension Omsesidigt acquired a new position in Danaher during the fourth quarter valued at $161,994,000. Finally, Harris Associates L P boosted its holdings in Danaher by 27.7% in the third quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock valued at $735,343,000 after purchasing an additional 642,759 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR stock traded down $0.16 on Tuesday, reaching $246.66. 3,940,969 shares of the company were exchanged, compared to its average volume of 2,785,271. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The business has a 50-day moving average price of $248.80 and a 200 day moving average price of $231.53. The company has a market cap of $182.70 billion, a price-to-earnings ratio of 41.83, a P/E/G ratio of 3.80 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.36 EPS. Equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were issued a $0.27 dividend. The ex-dividend date was Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insiders Place Their Bets

In other news, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Insiders have sold a total of 106,565 shares of company stock valued at $26,641,364 in the last 90 days. 10.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on DHR shares. Robert W. Baird lifted their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Barclays boosted their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. TD Cowen raised their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Citigroup boosted their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Finally, KeyCorp raised their price target on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $269.64.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.